ProShare Advisors’s ALX Oncology ALXO Stock Holding History

ProShare Advisors’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29.2K	Buy	+14,125	New	+$25.3K	﹤0.01%	1891
2022 Q1	–	Sell	-9,579	Closed	-$205K	–	2202
2021 Q4	$205K	Sell	9,579 -1,315	-12%	-$56.7K	﹤0.01%	2018
2021 Q3	$805K	Sell	10,894 -934	-8%	-$62.3K	﹤0.01%	984
2021 Q2	$647K	Buy	11,828 +1,665	+16%	+$99.6K	﹤0.01%	1343
2021 Q1	$749K	Buy	10,163 +2,278	+29%	+$179K	﹤0.01%	1167
2020 Q4	$680K	Buy	+7,885	New	+$474K	﹤0.01%	1079

Other funds holding ALXO

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

ProShare Advisors's ALXO Position: Q2 2026 in Review

ProShare Advisors opened a new position in ALX Oncology (ALXO) in Q2 2026: 14,125 shares worth $29.2K. The stake represents ﹤0.01% of the portfolio and ranks #1891 among its holdings. This is a return to the name: ProShare Advisors previously reported a position in ALXO as recently as Q4 2021.

ProShare Advisors first reported a position in ALXO in Q4 2020 and has held it in 6 quarters since. The position peaked at $805K in Q3 2021. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

ProShare Advisors held 14,125 shares of ALX Oncology worth $29.2K as of Q2 2026.
ALX Oncology was a new ProShare Advisors position in Q2 2026.
ALX Oncology made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1891 holding.
ProShare Advisors first reported a position in ALX Oncology in Q4 2020 and has held it in 6 quarters since.
ProShare Advisors's ALX Oncology position peaked at $805K in Q3 2021.
94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.